Similarly, a different trial evaluating low-dose ipilimumab plus nivolumab in NSCLC patients reported an ORR of 57% in patients with tumor PD-L1 expression ≥1 and 92% in patients with tumor PD-L1 expression ≥50% (CheckMate 012) [60]. Here, CD274 is linked to neoplasm.